REVENUE RECOGNITION AND COLLABORATIVE ARRANGEMENTS (Tables)

12 Months Ended

Dec. 31, 2020

REVENUE RECOGNITION AND COLLABORATIVE ARRANGEMENTS

Schedule of net revenue from collaborative arrangements

Net revenue recognized under our GSK Agreements was as follows:

	Year Ended December 31,
(In thousands)	2020		2019		2018
Royalties from a related party - RELVAR/BREO	$	221,536	$	189,424	$	220,162
Royalties from a related party - ANORO		45,992		42,625		41,286
Royalties from a related party - TRELEGY		73,089		42,790		13,379
Total royalties from a related party		340,617		274,839		274,827
Less: amortization of capitalized fees paid to a related party		(13,823)		(13,823)		(13,823)
Royalty revenue		326,794		261,016		261,004
Strategic alliance  - MABA program		10,000		—		—
Total net revenue from GSK	$	336,794	$	261,016	$	261,004